Rising Adoption of Pets to Soar the Demand for Isoxazoline Drugs Market

Introduction

Isoxazoline is a form of oral insecticide that currently carries the license for parasite control among companion animals such as dogs and cats. These types of drugs were initially introduced in 2010 as pesticides, and later in 2013, they were introduced as veterinary drugs against fleas and ticks in dogs. They are also effective against other external parasites and agricultural parasites.

Various classes of isoxazoline include fluralaner, lotilaner, sarolaner, and afoxolaner. These classes of drugs are used singly or in combination with other types of drugs such as fluralaner and moxidectin, sarolaner, moxidectin and pyrantel, and selamectin and sarolaner. 

Increasing Prevalence of Generalized Demodicosis Among Dogs to Bolster Growth

The rising occurrence of demodicosis (red mange) among dogs is expected to contribute to the market growth during the forecast period. An ongoing study revealed that isoxazoline combined with imidacloprid and moxidectin in parasitology reaps more viable benefits than any other combinative drugs. Increased demands have compelled prominent players to modernize their manufacturing capacities due to the increasing commonness of dosage being distributed. Due to rising processes being introduced, investments are being subverted to increase the efficacies of the ongoing treatment.

Rising Consumer Spending and Increasing Dog Pool for Adoption to Provide New Opportunities for Isoxazoline to Flourish 

According to the American Pet Products Association (APPA), the sales for the pet industry crossed USD 100 billion in 2020 for the first time. Increasing adoption of pet shopping and supplies through e-commerce has utilized a previously untapped distribution channel. Increased focus on pet well-being led to rising instances of in-person veterinary visits, triggering an outburst of isoxazoline drugs usage. The America Kennel Club noted an increase in the adoption of German Shepherd, Golden Retriever, Labrador Retriever, and Bulldogs, which increased the chance of isoxazoline usage due to their furry nature.

Impact of COVID-19

During the initial stages of the pandemic, various nations-imposed lockdowns to curb the spread of the virus, leading to increased anxiety and a sense of loneliness among the general population. This has led to a surge in pet adoptions during that period. The American Kennel Club noted that the number of US households having at least one dog increased to 69 million in 2020, an increase of 54% from 2018. Pet owners and manufacturers established online delivery systems and added attributes such as tracking and pre-ordering consumables based on your last order. This ease of transaction further created growth for the isoxazoline market during the pandemic. 

Regional Insights

In the Americas, the growth of isoxazoline drugs is due to the increasing adoption of companion animals and rising expenditure on pet care. This region holds the majority of the market share and is expected to grow at a CAGR of 18.16% during the projected period. The European market is predicted to grow at a CAGR of 18.11% from the rising adoption of dogs. Further, increasing awareness about preventing and controlling fleas and ticks in dogs has increased the demand for these drugs. 

Asia-Pacific is anticipated to grow at the highest CAGR of 18.35% during the forecast period. The largest share of this region is contributed by rising disposable income and increasing adoption of companion animals, especially dogs and cats. Countries such as China and India are anticipated to provide greater opportunities due to a lack of regional players. The Middle East and Africa held a minor share of the market. 

 

Key Highlights

• The global isoxazoline drugs market was valued at USD 1,305.76 million in 2021, and it is predicted to increase at a CAGR of 18.00% by 2030.
• Based on product type, the market is categorized into fluralaner, sarolaner, lotilaner, and afoxolaner. Afoxolaner is predicted to grow at a CAGR of 18.09% during the forecast period.
• By pet type, the market is segmented into dogs and cats. The dogs' segment acquired ~67% of the market in 2021. It is expected to grow at a CAGR of 18.11%
• Geographically, the market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

 

Competitive Players

Recent Developments

Recent Market News

• In January 2022, Zoetis received approval from the US FDA for a new label indication for Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) for the treatment of tick infection in dogs. 
• In June 2021, Elanco launched Credelio Plus, a chewy monthly tablet for treating fleas, worms, and ticks in dogs. 
• In May 2021, Elanco introduced Credelio CAT, an oral ticks and flea product for cats. This drug starts killing fleas within 6 hours. 
• In May 2021, Zoetis announced US FDA approved a new label for Simparica chewables to prevent Borrelia burgdorferi infections for dogs at least six months of age or more. 
• In January 2021, Boehringer Ingelheim announced they received marketing authorization from the European Medicines Agency (EMA) and European Commission for NexGard COMBO topical solution for cats.
• In July 2020, Boehringer Ingelheim launched NexGard, a ticks and flea repellent in India. 
• In July 2020, Merck Animal Health received US FDA approval for BRAVECTO (fluralaner) 1-MONTH Chews for dogs and puppies eight weeks of age and older. This product is indicated for treating and preventing flea infestations and tick infestations (Ixodes scapularis, Dermacentor variabilis, and Rhipicephalus sanguineus). It is also indicated for treatment and control of Amblyomma americanum (lone star tick). 
• In February 2020, Zoetis received US FDA approval for Simparica Trio, which provides protection from fleas and ticks, heartworms, roundworms, and hookworms. 
• In May 2019, Merck Animal Health announced the launch of BRAVECTO Cares, an educational campaign. Through this campaign, they showcased the critical role that service dogs play and the importance of keeping them healthy, including protecting them from ticks and fleas.
• In November 2018, Boehringer Ingelheim announced that they received approval to expand the label claims for NexGard to treat two severe skin diseases in dogs. These new approvals include the treatment of cutaneous diseases demodicosis and sarcoptic mange in Australia and Europe. 
• In August 2018, NecGard SPECTRA was launched in China as the first oral endoectocide for the treatment of ticks in dogs.

Segmentation

Isoxazoline Drugs Market Segmentation

By Product Type

• Fluralaner
• Sarolaner
• Lotilaner
• Afoxolaner

By Pet Type

• Dogs
• Cats

By Regions

• Americas
• Europe
• Asia-Pacific
• The Middle East and Africa